Crenezumab

Feb 10, 2020

Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study

Nov 02, 2019

Green Valley Announces NMPA Approval Of Oligomannate For Mild To Moderate Alzheimer's Disease

Oct 22, 2019

Neurimmune Welcomes Biogen's News on Clinical Benefit of Aducanumab

Mar 21, 2019

Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease

Jan 31, 2019

Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease

Dec 19, 2018

WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership

Nov 01, 2018

LuMind Research Down Syndrome Foundation Launches the Down Syndrome Clinical Trials Network

Nov 01, 2017

New Report Highlights Innovation in Alzheimer's Clinical Trials

Jun 15, 2017

Pharmaceutical Leaders Pave the Way to New Alzheimer's Treatments